ALT logo

Altimmune (ALT) Company Overview

Profile

Full Name:

Altimmune, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 26, 2017

Indexes:

Not included

Description:

Altimmune is a biotechnology company focused on developing innovative treatments for infectious diseases and immune-related conditions. They create therapies that aim to enhance the body’s immune response, helping to improve health outcomes. Their research includes vaccines and treatments for various diseases, including respiratory and liver conditions.

Key Details

Price

$6.67

Annual Revenue

$426.00 K(+726.47% YoY)

Annual EPS

-$1.66(+8.29% YoY)

Annual ROE

-46.63%

Beta

2.20

Events Calendar

Earnings

Next earnings date:

Mar 27, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Jan 20, 2017
Splits

Next split:

N/A

Recent split:

Sep 14, 2018

Analyst ratings

Recent major analysts updates

Feb 5, 25 HC Wainwright & Co.
Buy
Jan 23, 25 HC Wainwright & Co.
Buy
Jan 22, 25 HC Wainwright & Co.
Buy
Jan 8, 25 Stifel
Buy
Nov 14, 24 HC Wainwright & Co.
Buy
Nov 12, 24 UBS
Buy
Aug 12, 24 B. Riley Securities
Buy
Jun 25, 24 B. Riley Securities
Buy
Jun 21, 24 Piper Sandler
Overweight
May 14, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Dividend per share

Dividend yield

Other

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

ALT5 Sigma Partners With Odoo to Offer Crypto Payments Capabilities Through Odoo Marketplace
ALT5 Sigma Partners With Odoo to Offer Crypto Payments Capabilities Through Odoo Marketplace
ALT5 Sigma Partners With Odoo to Offer Crypto Payments Capabilities Through Odoo Marketplace
ALT
accessnewswire.comFebruary 3, 2025

-Odoo is the most installed business software in the world, used by over 13,000,000 users worldwide ranging from startup companies (1 user) to large enterprises (300,000+ users)- LAS VEGAS, NV / ACCESS Newswire / February 3, 2025 / ALT5 Sigma Corporation (Nasdaq:ALTS), a leading fintech innovator specializing in blockchain-powered technologies, is pleased to announce a partnership with Odoo, a globally recognized provider of fully integrated business applications. This collaboration will integrate ALT5 Pay into Odoo's suite of POS, eCommerce, and ERP systems, empowering Odoo's 13 million users across 170 countries with seamless cryptocurrency payment solutions.

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
ALT
globenewswire.comJanuary 29, 2025

GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:

ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing
ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing
ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing
ALT
accesswire.comJanuary 15, 2025

LAS VEGAS, NV / ACCESSWIRE / January 15, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a prominent innovator in the cryptocurrency sector, is pleased to announce a partnership with Hashtag Influencer, an advanced AI-powered SocialFi platform. This collaboration aims to enhance the influencer marketing landscape by enabling influencers in the gig economy to seamlessly and compliantly accept cryptocurrency payments for advertising deals with brands through social media platforms such as Instagram, Facebook, YouTube, and LinkedIn.

Why Altimmune Was Such a Robustly Healthy Stock on Thursday
Why Altimmune Was Such a Robustly Healthy Stock on Thursday
Why Altimmune Was Such a Robustly Healthy Stock on Thursday
ALT
fool.comDecember 19, 2024

Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized stock index; investors greeted this news by trading the company's stock up by more than 3% on the day.

Altimmune Added to Nasdaq Biotechnology Index
Altimmune Added to Nasdaq Biotechnology Index
Altimmune Added to Nasdaq Biotechnology Index
ALT
globenewswire.comDecember 19, 2024

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.

Altimmune 2025: Redefining Obesity And MASH Treatment
Altimmune 2025: Redefining Obesity And MASH Treatment
Altimmune 2025: Redefining Obesity And MASH Treatment
ALT
seekingalpha.comDecember 16, 2024

Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in Pemvidutide. Valuation of on-label and off-label use of Pemvidutide across all indications and comorbidities show that Altimmune is significantly undervalued at current share prices, factoring in all risks.

Altimmune CEO on what's next for its experimental obesity drug
Altimmune CEO on what's next for its experimental obesity drug
Altimmune CEO on what's next for its experimental obesity drug
ALT
youtube.comDecember 3, 2024

Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, potential commercial partnership and more.

Altimmune Stock Up More Than 25% in a Month: Here's Why
Altimmune Stock Up More Than 25% in a Month: Here's Why
Altimmune Stock Up More Than 25% in a Month: Here's Why
ALT
zacks.comDecember 2, 2024

ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock.

Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune to Participate at Two Upcoming Investor Conferences
ALT
globenewswire.comNovember 26, 2024

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
ALT
globenewswire.comNovember 15, 2024

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids

FAQ

  • What is the ticker symbol for Altimmune?
  • Does Altimmune pay dividends?
  • What sector is Altimmune in?
  • What industry is Altimmune in?
  • What country is Altimmune based in?
  • When did Altimmune go public?
  • Is Altimmune in the S&P 500?
  • Is Altimmune in the NASDAQ 100?
  • Is Altimmune in the Dow Jones?
  • When was Altimmune's last earnings report?
  • When does Altimmune report earnings?
  • Should I buy Altimmune stock now?

What is the ticker symbol for Altimmune?

The ticker symbol for Altimmune is NASDAQ:ALT

Does Altimmune pay dividends?

No, Altimmune does not pay dividends

What sector is Altimmune in?

Altimmune is in the Healthcare sector

What industry is Altimmune in?

Altimmune is in the Biotechnology industry

What country is Altimmune based in?

Altimmune is headquartered in United States

When did Altimmune go public?

Altimmune's initial public offering (IPO) was on May 26, 2017

Is Altimmune in the S&P 500?

No, Altimmune is not included in the S&P 500 index

Is Altimmune in the NASDAQ 100?

No, Altimmune is not included in the NASDAQ 100 index

Is Altimmune in the Dow Jones?

No, Altimmune is not included in the Dow Jones index

When was Altimmune's last earnings report?

Altimmune's most recent earnings report was on Nov 12, 2024

When does Altimmune report earnings?

The next expected earnings date for Altimmune is Mar 27, 2025

Should I buy Altimmune stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions